This study was closed after the determination of the recommended expansion dose owing to the modest activity of the regimen, the changing landscape of treatment with chemotherapy plus ICI becoming standard first-line therapy, and the development of inhibitors targeting RAS-mutated lung cancers, particularly KRAS G12C, which is the most frequent KRAS amino acid substitution in NSCLC. Here, KRAS is linked to non-small cell lung carcinoma.